PURPOSE: Multiple myeloma is an incurable disease, for which the development of new therapeutic approaches is required. Here, we report on the efficacy of recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to inhibit tumor progression and bone destruction in a xenogeneic model of human multiple myeloma. EXPERIMENTAL DESIGN: We established a mouse model of myeloma, in which Apo2L/TRAIL-sensitive RPMI-8226 or KMS-11 cells, tagged with a triple reporter gene construct (NES-HSV-TK/GFP/Luc), were transplanted directly into the tibial marrow cavity of nude mice. Tumor burden was monitored progressively by bioluminescence imaging and the development of myeloma-induced osteolysis was measured using high resolution in vivo micro-computed tomography. RESULTS: Tumor burden increased progressively in the tibial marrow cavity of mice transplanted with Apo2L/TRAIL-sensitive RPMI-8226 or KMS-11 cells associated with extensive osteolysis directly in the area of cancer cell transplantation. Treatment of mice with recombinant soluble Apo2L/TRAIL reduced myeloma burden in the bone marrow cavity and significantly protected against myeloma-induced osteolysis. The protective effects of Apo2L/TRAIL treatment on bone were mediated by the direct apoptotic actions of Apo2L/TRAIL on myeloma cells within the bone microenvironment. CONCLUSIONS: This is the first in vivo study that investigates the efficacy of recombinant Apo2L/TRAIL on myeloma burden within the bone microenvironment and associated myeloma-induced bone destruction. Our findings that recombinant soluble Apo2L/TRAIL reduces myeloma burden within the bone microenvironment and protects the bone from myeloma-induced bone destruction argue against an inhibitory role of osteoprotegerin in Apo2L/TRAIL-induced apoptosis in vivo and highlight the need to clinically evaluate Apo2L/TRAIL in patients with multiple myeloma.
PURPOSE:Multiple myeloma is an incurable disease, for which the development of new therapeutic approaches is required. Here, we report on the efficacy of recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to inhibit tumor progression and bone destruction in a xenogeneic model of humanmultiple myeloma. EXPERIMENTAL DESIGN: We established a mouse model of myeloma, in which Apo2L/TRAIL-sensitive RPMI-8226 or KMS-11 cells, tagged with a triple reporter gene construct (NES-HSV-TK/GFP/Luc), were transplanted directly into the tibial marrow cavity of nude mice. Tumor burden was monitored progressively by bioluminescence imaging and the development of myeloma-induced osteolysis was measured using high resolution in vivo micro-computed tomography. RESULTS:Tumor burden increased progressively in the tibial marrow cavity of mice transplanted with Apo2L/TRAIL-sensitive RPMI-8226 or KMS-11 cells associated with extensive osteolysis directly in the area of cancer cell transplantation. Treatment of mice with recombinant soluble Apo2L/TRAIL reduced myeloma burden in the bone marrow cavity and significantly protected against myeloma-induced osteolysis. The protective effects of Apo2L/TRAIL treatment on bone were mediated by the direct apoptotic actions of Apo2L/TRAIL on myeloma cells within the bone microenvironment. CONCLUSIONS: This is the first in vivo study that investigates the efficacy of recombinant Apo2L/TRAIL on myeloma burden within the bone microenvironment and associated myeloma-induced bone destruction. Our findings that recombinant soluble Apo2L/TRAIL reduces myeloma burden within the bone microenvironment and protects the bone from myeloma-induced bone destruction argue against an inhibitory role of osteoprotegerin in Apo2L/TRAIL-induced apoptosis in vivo and highlight the need to clinically evaluate Apo2L/TRAIL in patients with multiple myeloma.
Authors: A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle Journal: J Biol Chem Date: 2000-07-28 Impact factor: 5.157
Authors: C S Mitsiades; S P Treon; N Mitsiades; Y Shima; P Richardson; R Schlossman; T Hideshima; K C Anderson Journal: Blood Date: 2001-08-01 Impact factor: 22.113
Authors: N A Sims; P Clément-Lacroix; F Da Ponte; Y Bouali; N Binart; R Moriggl; V Goffin; K Coschigano; M Gaillard-Kelly; J Kopchick; R Baron; P A Kelly Journal: J Clin Invest Date: 2000-11 Impact factor: 14.808
Authors: D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan Journal: Mol Cancer Res Date: 2015-01-30 Impact factor: 5.852
Authors: Agatha Labrinidis; Shelley Hay; Vasilios Liapis; Vladimir Ponomarev; David M Findlay; Andreas Evdokiou Journal: Clin Cancer Res Date: 2009-04-28 Impact factor: 12.531
Authors: B Grubor-Bauk; W Yu; D Wijesundara; J Gummow; T Garrod; A J Brennan; I Voskoboinik; E J Gowans Journal: Gene Ther Date: 2015-10-01 Impact factor: 5.250
Authors: Irene Zinonos; Agatha Labrinidis; Michelle Lee; Vasilios Liapis; Shelley Hay; Vladimir Ponomarev; Peter Diamond; Andrew C W Zannettino; David M Findlay; Andreas Evdokiou Journal: Mol Cancer Ther Date: 2009-10-06 Impact factor: 6.261